Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04577326 · ClinicalTrials.gov registry record · Phase 1
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
A Phase 1 study of Malignant Pleural Mesothelioma (MPM), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04577326 is a Phase 1 study of Malignant Pleural Mesothelioma (MPM) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 14 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04577326, a Phase 1 study of Malignant Pleural Mesothelioma (MPM), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T cell treatment with an anti-PD1 component is being given to people.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL CAR T cells
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04577326
The ClinicalTrials.gov registry entry for NCT04577326 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Pleural Mesothelioma (MPM) appearing as the primary indexed condition, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT04577326 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04577326 about?
NCT04577326 is a clinical study titled "Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma". This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T c...
What is the current status of trial NCT04577326?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2020-09-30. Estimated completion is 2026-09-30.
What conditions does trial NCT04577326 study?
This clinical trial studies the following conditions: Malignant Pleural Mesothelioma (MPM).
What interventions are being tested in trial NCT04577326?
The interventions under investigation include: cyclophosphamide (DRUG), CAR T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04577326?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04577326 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Pleural Mesothelioma (MPM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.